This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garland, J. S.
Right arrow Articles by McAuliffe, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garland, J. S.
Right arrow Articles by McAuliffe, T. L.
Related Collections
Right arrow Premature & Newborn

PEDIATRICS Vol. 104 No. 1 July 1999, pp. 91-99

A Three-day Course of Dexamethasone Therapy to Prevent Chronic Lung Disease in Ventilated Neonates: A Randomized Trial

Received Oct 23, 1998; accepted Apr 7, 1999.

Jeffery S. Garland*, Dagger , Colleen P. Alex*, Thomas H. Pauly§, Vicki L. Whitehead§, Joseph Brandparallel , James F. Winstonparallel , David P. Samuelsparallel , and Timothy L. McAuliffe

From the Departments of Pediatrics at * St Joseph's Hospital, Milwaukee, Wisconsin; Dagger  St Mary's Hospital, Milwaukee, Wisconsin; § University of Kentucky, Lexington, Kentucky; parallel  St Vincent Hospital, Green Bay, Wisconsin; and the  Division of Biostatistics at the Medical College of Wisconsin, Milwaukee, Wisconsin.

Background.  Although several trials of early dexamethasone therapy have been completed to determine if such therapy would reduce mortality and chronic lung disease (CLD) in infants with respiratory distress, optimal duration and side effects of such therapy remain unknown.

Purpose.  The purpose of this study was: 1) to determine if a 3-day course of early dexamethasone therapy would reduce CLD and increase survival without CLD in neonates who received surfactant therapy for respiratory distress syndrome and 2) to determine adverse effects associated with such therapy.

Design.  This was a prospective multicenter randomized trial comparing a 3-day course of dexamethasone therapy beginning at 24 to 48 hours of life to placebo therapy. Two hundred forty-one neonates (dexamethasone n = 118, placebo n = 123), who weighed between 500 g and 1500 g, received surfactant therapy, and were at significant risk for CLD or death using a model to predict CLD or death at 24 hours of life, were enrolled in the trial. Infants randomized to receive early dexamethasone were given 6 doses of dexamethasone at 12-hour intervals beginning at 24 to 48 hours of life. The primary outcomes compared were survival without CLD and CLD. CLD was defined by the need for supplemental oxygen at the gestational age of 36 weeks. Complication rates and adverse effects of study drug therapy were also compared.

Results.  Neonates randomized to early dexamethasone treatment were more likely to survive without CLD (RR: 1.3; 95% CI: 1.03, 1.7) and were less likely to develop CLD (RR: 0.6; CI: 0.3, 0.98). Mortality rates were not significantly different. Subsequent dexamethasone therapy use was less in early dexamethasone-treated neonates (RR: 0.8; CI: 0.7, 0.96). Very early (<= 7 days of life) intestinal perforations were more common among dexamethasone-treated neonates (8% vs 1%).

Conclusion.  We conclude that an early 3-day course of dexamethasone therapy increases survival without CLD, reduces CLD, and reduces late dexamethasone therapy in high-risk, low birth weight infants who receive surfactant therapy for respiratory distress syndrome. Potential benefits of early dexamethasone therapy at the dosing schedule used in this trial need to be weighed against the risk for early intestinal perforation.  Key words:  low birth weight infants, respiratory distress syndrome, dexamethasone, chronic lung disease.




This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
P. Nykanen, T. Raivio, K. Heinonen, O. A Janne, and R. Voutilainen
Circulating glucocorticoid bioactivity and serum cortisol concentrations in premature infants: the influence of exogenous glucocorticoids and clinical factors
Eur. J. Endocrinol., May 1, 2007; 156(5): 577 - 583.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
P. V. Gordon
Reopening the debate on corticosteroids: to the editor.
Pediatrics, June 1, 2006; 117(6): 2318 - 2320.
[Full Text] [PDF]

Home page
 NeoReviewsHome page
J. V. Aranda and R. Thomas
Pharmacology Review: Intravenous Ibuprofen for Preterm Newborns
NeoReviews, November 1, 2005; 6(11): e516 - e523.
[Full Text] [PDF]

Home page
 J EndocrinolHome page
P V Gordon, J B Paxton, and N S Fox
The cellular repressor of E1A-stimulated genes mediates glucocorticoid-induced loss of the type-2 IGF receptor in ileal epithelial cells
J. Endocrinol., May 1, 2005; 185(2): 265 - 273.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. F. Yeh, Y. J. Lin, H. C. Lin, C. C. Huang, W. S. Hsieh, C. H. Lin, and C. H. Tsai
Outcomes at School Age after Postnatal Dexamethasone Therapy for Lung Disease of Prematurity
N. Engl. J. Med., March 25, 2004; 350(13): 1304 - 1313.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
W A Dik, R J McAnulty, M A Versnel, B A E Naber, L J I Zimmermann, G J Laurent, and S E Mutsaers
Short course dexamethasone treatment following injury inhibits bleomycin induced fibrosis in rats
Thorax, September 1, 2003; 58(9): 765 - 771.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Statement on the Care of the Child with Chronic Lung Disease of Infancy and Childhood
Am. J. Respir. Crit. Care Med., August 1, 2003; 168(3): 356 - 396.
[Full Text] [PDF]

Home page
 PediatricsHome page
P. Lassus, I. Nupponen, A. Kari, M. Pohjavuori, and S. Andersson
Early Postnatal Dexamethasone Decreases Hepatocyte Growth Factor in Tracheal Aspirate Fluid From Premature Infants
Pediatrics, October 1, 2002; 110(4): 768 - 771.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. C. Rathman, B. Lewis, and R. J. McMahon
Acute glucocorticoid treatment increases urinary biotin excretion and serum biotin
Am J Physiol Endocrinol Metab, March 1, 2002; 282(3): E643 - E649.
[Abstract] [Full Text] [PDF]

Home page
 NeoReviewsHome page
B. A. Banks
Postnatal Dexamethasone for Bronchopulmonary Dysplasia: A Systematic Review and Meta-analysis of 20 Years of Clinical Trials
NeoReviews, February 1, 2002; 3(2): e24 - 34.
[Full Text]

Home page
 PediatricsHome page
The Vermont Oxford Network Steroid Study Group
Early Postnatal Dexamethasone Therapy for the Prevention of Chronic Lung Disease
Pediatrics, September 1, 2001; 108(3): 741 - 748.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. L. RAMSAY, F. J. DeMAYO, S. E. HEGEMIER, M. E. WEARDEN, C. V. SMITH, and S. E. WELTY
Clara Cell Secretory Protein Oxidation and Expression in Premature Infants Who Develop Bronchopulmonary Dysplasia
Am. J. Respir. Crit. Care Med., July 1, 2001; 164(1): 155 - 161.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
B. A. Banks, N. Stouffer, A. Cnaan, Y. Ning, J. D. Merrill, R. A. Ballard, P. L. Ballard, and the North American Thyrotropin-Releasing Hormone T
Association of Plasma Cortisol and Chronic Lung Disease in Preterm Infants
Pediatrics, March 1, 2001; 107(3): 494 - 498.
[Abstract] [Full Text]

Home page
 NEJMHome page
A. R. Stark, W. A. Carlo, J. E. Tyson, L.-A. Papile, L. L. Wright, S. Shankaran, E. F. Donovan, W. Oh, C. R. Bauer, S. Saha, et al.
Adverse Effects of Early Dexamethasone Treatment in Extremely-Low-Birth-Weight Infants
N. Engl. J. Med., January 11, 2001; 344(2): 95 - 101.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
R. E. Grunau, T. F. Oberlander, M. F. Whitfield, C. Fitzgerald, and S. K. Lee
Demographic and Therapeutic Determinants of Pain Reactivity in Very Low Birth Weight Neonates at 32 Weeks' Postconceptional Age
Pediatrics, January 1, 2001; 107(1): 105 - 112.
[Abstract] [Full Text]

Home page
 PediatricsHome page
P. C. Rimensberger, M. Beghetti, S. Hanquinet, and M. Berner
First Intention High-Frequency Oscillation With Early Lung Volume Optimization Improves Pulmonary Outcome in Very Low Birth Weight Infants With Respiratory Distress Syndrome
Pediatrics, June 1, 2000; 105(6): 1202 - 1208.
[Abstract] [Full Text]

Home page
 PediatricsHome page
R. A. Sinkin, H. S. Dweck, M. J. Horgan, K. J. Gallaher, C. Cox, W. M. Maniscalco, P. R. Chess, C. T. D'Angio, R. Guillet, J. W. Kendig, et al.
Early Dexamethasone---Attempting To Prevent Chronic Lung Disease
Pediatrics, March 1, 2000; 105(3): 542 - 548.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
W. Zhu, L. Song, H. Zhang, L. Matoney, E. LeCluyse, and B. Yan
Dexamethasone Differentially Regulates Expression of Carboxylesterase Genes in Humans and Rats
Drug Metab. Dispos., February 1, 2000; 28(2): 186 - 191.
[Abstract] [Full Text]